TapewireFind a company

person · Reporting owner

Mazzariello Gina

Disclosed activity across 1 company

Tapewire entity
21223
SEC CIK
0001913765

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Amylyx Pharmaceuticals, Inc.AMLX · Entity 259Chief Legal OfficerSeptember 10, 2026September 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Amylyx Pharmaceuticals, Inc.

Report date September 10, 2026 · Filed September 14, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect190,838 Ending reported balance After 2026-09-10 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-09-10 · Sale · Disposed 9,525 · Balance 190,849

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $33.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Row 2 · 2026-09-10 · Sale · Disposed 11 · Balance 190,838

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $33.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 10, 2026 Filed Sep 14, 2026 20:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 11 $33.34 $366.74
Disclosure

SEC source: 0001193125-26-390508 · ownership.xml · nonDerivative · entry 2

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,838

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Read SEC document
September 10, 2026 Filed Sep 14, 2026 20:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 9,525 $32.46 $309,139.59
Disclosure

SEC source: 0001193125-26-390508 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,849

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $33.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 18, 2026 Filed Aug 21, 2026 01:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantCommon Stock 21,284 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-359677 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,374

F1 · shares: The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026.

Read SEC document
July 10, 2026 Filed Jul 13, 2026 20:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 15,000 $17.61 $264,121.50
Disclosure

SEC source: 0001193125-26-301996 · ownership.xml · nonDerivative · entry 2

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 179,090

F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.15 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
July 09, 2026 Filed Jul 13, 2026 20:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 15,000 $18.32 $274,746.00
Disclosure

SEC source: 0001193125-26-301996 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 194,090

F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.92 to $18.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (Right to Buy) · Derivative 111,990 $0.00 Strike: $14.10 $0.00
Disclosure

SEC source: 0001193125-26-098439 · ownership.xml · derivative · entry 2

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,990

Underlying: Common Stock · 111,990 shares

Expires 2036-03-05

F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 20:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantCommon Stock 74,660 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-098439 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,090

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 21:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 6,844 $14.52 $99,378.30
Disclosure

SEC source: 0001193125-26-091436 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,430

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.400 to $15.070. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 23, 2026 Filed Feb 25, 2026 21:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 3,419 $14.14 $48,352.18
Disclosure

SEC source: 0001193125-26-071460 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,274

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.030 to $14.220. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 21:05 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 3,448 $14.65 $50,515.61
Disclosure

SEC source: 0001193125-26-037548 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,693

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.470 to $14.810. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
September 30, 2025 Filed Oct 2, 2025 20:15 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 8,828 $14.58 $128,668.98
Disclosure

SEC source: 0001193125-25-228342 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,141

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.355 to $15.075. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 13, 2025 Filed Aug 14, 2025 20:20 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 15,000 $8.34 $125,046.00
Disclosure

SEC source: 0000950170-25-108912 · ownership.xml · nonDerivative · entry 2

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,969

F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.13 to $8.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 12, 2025 Filed Aug 14, 2025 20:20 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 15,000 $8.07 $121,102.50
Disclosure

SEC source: 0000950170-25-108912 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,969

F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.82 to $8.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 22, 2025 Filed May 27, 2025 20:01 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GiftCommon Stock 1,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-077677 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,969

F1 · kind: Represents a bona fide gift for no consideration.

F1 · shares: Represents a bona fide gift for no consideration.

Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:12 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 9,192 $3.48 $31,954.15
Disclosure

SEC source: 0000950170-25-049560 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,969

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
March 06, 2025 Filed Mar 11, 2025 00:34 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 95,777 $0.00 Strike: $3.61 $0.00
Disclosure

SEC source: 0000950170-25-036717 · ownership.xml · derivative · entry 2

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,777

Underlying: Common Stock · 95,777 shares

Expires 2035-03-05

F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
March 06, 2025 Filed Mar 11, 2025 00:34 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantCommon Stock 63,851 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-036717 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,161

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:32 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 1,611 $3.12 $5,022.29
Disclosure

SEC source: 0000950170-25-033717 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,310

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.10 to $3.165. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 24, 2025 Filed Feb 26, 2025 21:35 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 4,169 $3.15 $13,144.86
Disclosure

SEC source: 0000950170-25-027833 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,921

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.14 to $3.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 03, 2025 Filed Feb 5, 2025 21:58 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 3,678 $3.49 $12,839.16
Disclosure

SEC source: 0000950170-25-014620 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,090

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.46 to $3.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
September 30, 2024 Filed Oct 2, 2024 22:48 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 8,709 $3.20 $27,840.06
Disclosure

SEC source: 0000950170-24-111805 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,768

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.12 to $3.235. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 15, 2024 Filed May 16, 2024 23:36 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 10,455 $1.88 $19,654.35
Disclosure

SEC source: 0000950170-24-061293 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,477

F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.82 to $1.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 16, 2024 Filed Apr 19, 2024 00:20 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 110,000 $0.00 Strike: $2.01 $0.00
Disclosure

SEC source: 0000950170-24-045695 · ownership.xml · derivative · entry 2

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2034-04-15

F2 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on April 16, 2025, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Read SEC document
April 16, 2024 Filed Apr 19, 2024 00:20 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantCommon Stock 80,560 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-045695 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,932

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest as follows: 33% on September 30, 2024, 33% on March 31, 2025 and 34% on September 30, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:05 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 1,540 $18.73 $28,840.97
Disclosure

SEC source: 0000950170-24-027921 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,372

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.62 to $18.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 23:13 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 55,000 $0.00 Strike: $17.56 $0.00
Disclosure

SEC source: 0000950170-24-022400 · ownership.xml · derivative · entry 2

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2034-02-25

F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 23:13 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantCommon Stock 36,667 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-022400 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,912

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Read SEC document
February 23, 2024 Filed Feb 27, 2024 22:59 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 2,838 $18.76 $53,230.66
Disclosure

SEC source: 0000950170-24-021472 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,245

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.61 to $19.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 20:35 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 6,164 $20.88 $128,686.44
Disclosure

SEC source: 0000950170-23-043242 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,083

F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.41 to $21.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 17, 2023 Filed May 19, 2023 20:07 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GiftCommon Stock 500 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-023240 · ownership.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,247

Read SEC document
March 16, 2023 Filed Mar 21, 2023 00:25 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 82,500 $0.00 Strike: $32.08 $0.00
Disclosure

SEC source: 0000899243-23-009177 · doc4.xml · derivative · entry 2

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,500

Underlying: Common Stock · 82,500 shares

Expires 2033-03-16

F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
March 16, 2023 Filed Mar 21, 2023 00:25 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantCommon Stock 18,333 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-009177 · doc4.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,747

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Read SEC document
February 24, 2023 Filed Feb 28, 2023 21:42 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 SaleCommon Stock 3,586 $34.49 $123,671.82
Disclosure

SEC source: 0000899243-23-006418 · doc4.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,414

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.25 to $34.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 22, 2022 Filed Feb 28, 2022 22:05 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 182,000 $0.00 Strike: $28.24 $0.00
Disclosure

SEC source: 0000899243-22-008101 · doc4.xml · derivative · entry 2

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,000

Underlying: Common Stock · 182,000 shares

Expires 2032-02-22

F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest 1/48 monthly over the 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
February 22, 2022 Filed Feb 28, 2022 22:05 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantCommon Stock 41,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-008101 · doc4.xml · nonDerivative · entry 1

Mazzariello Gina · CIK 0001913765 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,000

F1 · shares: The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.